Información de Savara Inc, dividendo de Savara Inc, actividades de los accionistas y más

Más Datos de Savara Inc Compañía

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Información de Savara Inc



Símbolo de cotizaciónSVRA

Nombre de la empresaSavara Inc

Fecha de salida a bolsaJun 25, 2001

Director ejecutivoPauls (Matthew)

Número de empleados59

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 25

Dirección6836 Bee Cave Road

CiudadAUSTIN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal78746

Teléfono151285113796

Sitio Webhttps://savarapharma.com/

Símbolo de cotizaciónSVRA

Fecha de salida a bolsaJun 25, 2001

Director ejecutivoPauls (Matthew)

Ejecutivos de Savara Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David A. Ramsay

Independent Director

2.49M

+20000.00%

Ms. Anne Erickson

Chief Business Officer

132.03K

-62960.00%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+20000.00%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

33.98K

-67760.00%

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

--

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

--

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Mr. Richard J. (Rick) Hawkins

Independent Director

--

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

--

Dr. Annigje (An) van Es-Johansson, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David A. Ramsay

Independent Director

2.49M

+20000.00%

Ms. Anne Erickson

Chief Business Officer

132.03K

-62960.00%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+20000.00%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

33.98K

-67760.00%

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

--

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: sáb., 7 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

Otro

60.35%

Accionistas

Proporción

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

Otro

60.35%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

30.38%

Venture Capital

19.47%

Hedge Fund

17.41%

Investment Advisor/Hedge Fund

13.35%

Private Equity

5.63%

Individual Investor

2.15%

Research Firm

1.54%

Bank and Trust

0.11%

Pension Fund

0.02%

Otro

9.92%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

294

181.72M

89.31%

-12.25M

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

New Enterprise Associates (NEA)

24.47M

12.03%

--

Nov 12, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

8.65%

--

Sep 30, 2025

Deerfield Management Company, L.P.

13.57M

6.67%

+5.61M

+70.38%

Oct 30, 2025

VR Adviser, LLC

12.68M

6.23%

+3.80M

+42.74%

Sep 30, 2025

TCG Crossover Management, LLC

12.36M

6.08%

--

Sep 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

5.63%

--

Sep 30, 2025

The Vanguard Group, Inc.

8.31M

4.09%

-121.57K

-1.44%

Sep 30, 2025

Nantahala Capital Management, LLC

8.78M

4.31%

+450.00K

+5.41%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

7.60M

3.74%

-943.37K

-11.04%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Virtus LifeSci Biotech Clinical Trials ETF

1.24%

Texas Capital Texas Small Cap Equity Index ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.13%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.07%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

ProShares Hedge Replication ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción1.24%

Texas Capital Texas Small Cap Equity Index ETF

Proporción0.24%

ProShares Ultra Nasdaq Biotechnology

Proporción0.13%

iShares Micro-Cap ETF

Proporción0.09%

Invesco Nasdaq Biotechnology ETF

Proporción0.07%

Texas Capital Texas Equity Index ETF

Proporción0.05%

iShares Biotechnology ETF

Proporción0.03%

ProShares Hedge Replication ETF

Proporción0.03%

Invesco RAFI US 1500 Small-Mid ETF

Proporción0.03%

iShares Russell 2000 Growth ETF

Proporción0.03%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos